CTI BioPharma Corp (NASDAQ:CTIC) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 312,700 shares, a growth of 70.5% from the August 30th total of 183,400 shares. Currently, 0.6% of the shares of the company are sold short. Based on an average trading volume of 137,100 shares, the days-to-cover ratio is presently 2.3 days.
Shares of CTIC stock traded up $0.03 on Friday, hitting $0.78. 49,610 shares of the stock were exchanged, compared to its average volume of 107,377. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 0.20. CTI BioPharma has a one year low of $0.60 and a one year high of $2.11. The firm’s 50 day moving average is $0.79 and its two-hundred day moving average is $0.84.
CTI BioPharma (NASDAQ:CTIC) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). The company had revenue of $0.42 million during the quarter. CTI BioPharma had a negative return on equity of 77.77% and a negative net margin of 225.01%.
Several hedge funds have recently bought and sold shares of CTIC. Renaissance Technologies LLC grew its stake in shares of CTI BioPharma by 24.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,596,587 shares of the biopharmaceutical company’s stock worth $1,372,000 after acquiring an additional 314,235 shares during the period. Fosun International Ltd grew its stake in shares of CTI BioPharma by 52.9% during the 2nd quarter. Fosun International Ltd now owns 459,274 shares of the biopharmaceutical company’s stock worth $390,000 after acquiring an additional 158,846 shares during the period. Jane Street Group LLC bought a new position in shares of CTI BioPharma during the 2nd quarter worth $119,000. Finally, SG Americas Securities LLC grew its stake in shares of CTI BioPharma by 44.0% during the 2nd quarter. SG Americas Securities LLC now owns 56,132 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 17,163 shares during the period. Institutional investors own 47.04% of the company’s stock.
About CTI BioPharma
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.
See Also: What is the Coverage Ratio?
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.